Impact of airflow limitation in chronic heart failure

Completed

• Conditions: airflow limitation; heartfailure; 10019280; 10038716

• Registration Number: NL-OMON37787
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

documented HeartFailure based on left ventricular dysfunction (irrespective of ejection fraction) (following current ESC guidelines)
age patients 50 years or older

Exclusion Criteria

Patients for whom spiromerty is contra indicated
patients with recent surgery, myocardial infarction or cardiac decompensation, lower respiratory tract infection or stroke

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Airflow limitation (AL), defined as FEV1/FVC < 0.70 (post bronchodilator)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>* Severity of AL, as defined by GOLD stages;<br /><br>* Restrictive AL, defined by FEV1/FVC *0.70 and a predicted FVC <80% (post<br /><br>bronchodilator)<br /><br>* AL as defined by FEV1 below the lower limit of normal (LLN), as measured by<br /><br>standardized spirometry equipment;<br /><br>* Diffusion capacity for carbon monoxide, using the single breath method.<br /><br>* Presence of past history of airflow limitation or COPD;<br /><br>* Health status questionnaire scores (mMRC dyspnoea score; Kansas City<br /><br>Cardiomyopathy Questionnaire, SF-12, and COPD Assessment Test (CAT));<br /><br><br /><br>* Healthcare utilisation: Number of emergency room visits and hospital<br /><br>admissions in previous 12 months.</p><br>